Ranbaxy launches the generic version of Evoxac in US
This launch clearly shows the increasing synergies between Ranbaxy and Daiichi Sankyo.
New Delhi, October 9, 2012: Ranbaxy Laboratories has launched the generic cevimeline hydrochloride capsules in the US market, under an agreement with Daiichi Sankyo Inc. It may be noted here that the capsules are used in treating Sjogren’s syndrome.
“Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy Laboratories, has launched the authorised generic cevimeline hydrochloride 30 mg capsules in the US market,” the company said in a statement today.
"This authorised generic form of Evoxac is an excellent example of optimising operational synergies that exists between Ranbaxy and Daiichi Sankyo, while accelerating our global business efforts," Arun Sawhney, CEO and Managing Director, Ranbaxy.
Going by the IMS-MAT June 2012 data, Evoxac generated total annualised sales of US$ 62.4 million in the US.
"We refer to the strategy of optimising diverse assets of both companies as our hybrid business model, that will allow both organisations to effectively seize opportunities across the full pharmaceutical value chain and product life-cycle, by leveraging the R&D and manufacturing of both Daiichi Sankyo and Ranbaxy," said Tsutomu Une, Chairman, Ranbaxy.
It is worth noting here that RPI (based in Jacksonville, Florida), is a wholly-owned subsidiary of Ranbaxy Laboratories Ltd, and is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.